by SWK Holdings | Sep 27, 2023 | 2023, archive
Guest Column | September 27, 2023 By Jody Staggs, president and CEO, SWK Holdings Small life science companies are the driving force behind groundbreaking medical innovations that have the potential to transform lives. Yet in a market with strong headwinds, securing...
by SWK Holdings | Sep 21, 2023 | 2023, archive
Introduction The SWK underwriting process generally consists of an approximate four-week diligence period followed by an approximate four-week legal documentation process. Key steps in SWK’s process include data review, key opinion leader (“KOL”) calls, customer...
by SWK Holdings | Jul 6, 2022 | 2022, archive
Guest Column originally published in Outsourced Pharma, June 29, 2022 The Federal Reserve’s move to raise interest rates to battle inflation – now running at approximately 8% annually – has altered the risk and return for investors who are dealing with rising...
by SWK Holdings | Jun 30, 2022 | 2022, archive
The primary motivation for growth stage companies to explore venture debt as a source of funding is to avoid the dilution that results from a round of equity financing. While venture debt will certainly be much less dilutive than an equity raise, prospective borrowers...
by SWK Holdings | Dec 17, 2021 | 2021, archive
At SWK, we believe that financial covenants and the process of setting mutually agreeable covenant levels play an important role in the lender/borrower relationship. A lender’s willingness to engage in the discussions and accommodate the requests outlined herein...
